Investigation of lymphocyte depletion and repopulation using alemtuzumab (Campath-1H) in cynomolgus monkeys

American Journal of Transplantation

Volumn 10, Issue 4, 2010, Pages 773-783

  Van Der Windt, D J ^a,b,c   Smetanka, C ^a   MacEdo, C ^a   He, J ^b   Lakomy, R ^b   Bottino, R ^b   Ekser, B ^a   Echeverri, G J ^a,d   Metes, D ^a,e   Ijzermans, J N M ^c   Trucco, M ^b   Cooper, D K C ^a   Lakkis, F G ^a,e  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^b CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

^c ERASMUS MEDICAL CENTER   (Netherlands)

^d FUNDACIÓN VALLE DEL LILI   (Colombia)

^e UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Alemtuzumab; Campath 1H; Cynomolgus; Flow cytometry; Monkey; Nonhuman primate

Indexed keywords

ALEMTUZUMAB; CD20 ANTIGEN; CD45RA ANTIGEN; CD52 ANTIGEN; GRANULOCYTE COLONY STIMULATING FACTOR; L SELECTIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; THYMOCYTE ANTIBODY;

AGGLUTINATION TEST; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; B CELL DEPLETION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFICACY; EXPERIMENTAL MONKEY; FLOW CYTOMETRY; IMMUNOSUPPRESSIVE TREATMENT; LYMPH NODE; LYMPHOCYTE DEPLETION; LYMPHOCYTE FUNCTION; LYMPHOCYTE REPOPULATION; MEMORY CELL; NEUTROPENIA; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; QUANTITATIVE STUDY; SCREENING TEST; T CELL DEPLETION;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; ANTIGENS, CD; CELL DIVISION; FLOW CYTOMETRY; IMMUNOPHENOTYPING; LYMPHOCYTE DEPLETION; LYMPHOCYTES; MACACA FASCICULARIS;

EID: 77949846514     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2010.03050.x     Document Type: Article

References (32)

1. Hale G, Dyer MJ, Clark MR et al. Remission induction in non-Hodgkin lymphoma with reshaped human monoclonal antibody CAMPATH-1H. Lancet 1988 2 : 1394 1399.
2. Ciancio G, Burke GW, Gaynor JJ et al. A randomized trial of thymoglobulin vs. alemtuzumab (with lower dose maintenance immunosuppression) vs. daclizumab in renal transplantation at 24 months of follow-up. Clin Transplant 2008 22 : 200 210.
3. Margreiter R, Klempnauer J, Neuhaus P, Muehlbacher F, Boesmueller C, Calne RY. Alemtuzumab (Campath-1H) and tacrolimus monotherapy after renal transplantation: Results of a prospective randomized trial. Am J Transplant 2008 8 : 1480 1485.
4. Pascual J, Bloom D, Torrealba J et al. Calcineurin inhibitor withdrawal after renal transplantation with alemtuzumab: Clinical outcomes and effect on T-regulatory cells. Am J Transplant 2008 8 : 1529 1536.
5. Tan HP, Donaldson J, Basu A et al. Two hundred living donor kidney transplantations under alemtuzumab induction and tacrolimus monotherapy: 3-year follow-up. Am J Transplant 2009 9 : 355 366
6. Newell KA, Cendales LC, Kirk AD. Finding the right job for the tool: Alemtuzumab and its role in renal transplantation. Am J Transplant 2008 8 : 1363 1364.
7. Hale G, Hoang T, Prospero T, Watt SM, Waldmann H. Removal of T cells from bone marrow for transplantation: Comparison of rat monoclonal anti-lymphocyte antibodies of different isotypes. Mol Biol Med 1983 1 : 305 319.
8. Hale G, Swirsky DM, Hayhoe FG, Waldmann H. Effects of monoclonal anti-lymphocyte antibodies in vivo in monkeys and humans. Mol Biol Med 1983 1 : 321 334.
9. de Giorgi L, Brent L, Linch D, Nicolaides K, Rodeck CH. The inheritance of a Macaca fascicularis red cell antigen detected by CAMPATH-1 antibody. Immunol Lett 1987 15 : 101 103.
10. Xia MQ, Hale G, Lifely MR et al. Structure of the CAMPATH-1 antigen, a glycosylphosphatidylinositol-anchored glycoprotein which is an exceptionally good target for complement lysis. Biochem J 1993 293 : 633 640.
11. Perry AC, Jones R, Hall L. Identification of an abundant monkey epididymal transcript encoding a homologue of human CAMPATH-1 antigen precursor. Biochim Biophys Acta 1992 1171 : 122 124.
12. Xia MQ, Tone M, Packman L, Hale G, Waldmann H. Characterization of the CAMPATH-1 (CDw52) antigen: Biochemical analysis and cDNA cloning reveal an unusually small peptide backbone. Eur J Immunol 1991 21 : 1677 1684.
13. http://www.emea.europa.eu/humandocs/PDFs/EPAR/mabcampath/130101en6.pdf, European Agency for the Evaluation of Medicinal Products.
14. Carter DL, Shieh TM, Blosser RL et al. CD56 identifies monocytes and not natural killer cells in rhesus macaques. Cytometry 1999 37 : 41 50.
15. DeMaria MA, Casto M, O'Connell M, Johnson RP, Rosenzweig M. Characterization of lymphocyte subsets in rhesus macaques during the first year of life. Eur J Haematol 2000 65 : 245 257.
16. Cooper DKC, Ye Y, Niekrasz M. Heart transplantation in primates. In : Makowka L, Cramer DV, Sher L, eds. Experimental techniques in transplantation. Boca Raton, Florida : CRC Press, 1994 : 173 200.
17. Van Der Windt DJ, Bottino R, Casu A et al. Long-term controlled normoglycemia in diabetic non-human primates after transplantation with hCD46 transgenic porcine islets. Am J Transplant 2009 9 : 2716 2726.
18. Macedo C, Orkis EA, Popescu I et al. Contribution of naive and memory T-cell populations to the human alloimmune response. Am J Transplant 2009 9 : 2057 2066.
19. Stanglmaier M, Reis S, Hallek M. Rituximab and alemtuzumab induce a nonclassic, caspase-independent apoptotic pathway in B-lymphoid cell lines and in chronic lymphocytic leukemia cells. Ann Hematol 2004 83 : 634 645.
20. Liu C, Noorchashm H, Sutter JA et al. B lymphocyte-directed immunotherapy promotes long-term islet allograft survival in nonhuman primates. Nat Med 2007 13 : 1295 1298.
21. Rood PP, Bottino R, Balamurugan AN et al. Reduction of early graft loss after intraportal porcine islet transplantation in monkeys. Transplantation 2007 83 : 202 210.
22. Casu A, Bottino R, Balamurugan AN et al. Metabolic aspects of pig-to-monkey (Macaca fascicularis) islet transplantation: Implications for translation into clinical practice. Diabetologia 2008 51 : 120 129.
23. Morris EC, Rebello P, Thomson KJ et al. Pharmacokinetics of alemtuzumab used for in vivo and in vitro T-cell depletion in allogeneic transplantations: Relevance for early adoptive immunotherapy and infectious complications. Blood 2003 102 : 404 406.
24. Rebello P, Cwynarski K, Varughese M, Eades A, Apperley JF, Hale G. Pharmacokinetics of CAMPATH-1H in BMT patients. Cytotherapy 2001 3 : 261 267.
25. Noris M, Casiraghi F, Todeschini M et al. Regulatory T cells and T cell depletion: Role of immunosuppressive drugs. J Am Soc Nephrol 2007 18 : 1007 1018.
26. Ernst B, Lee DS, Chang JM, Sprent J, Surh CD. The peptide ligands mediating positive selection in the thymus control T cell survival and homeostatic proliferation in the periphery. Immunity 1999 11 : 173 181.
27. Sener A, Tang AL, Farber DL. Memory T-Cell predominance following T-cell depletional therapy derives from homeostatic expansion of naive T cells. Am J Transplant 2009 9 : 2615 2623.
28. Pearl JP, Parris J, Hale DA et al. Immunocompetent T-cells with a memory-like phenotype are the dominant cell type following antibody-mediated T-cell depletion. Am J Transplant 2005 5 : 465 474.
29. Trzonkowski P, Zilvetti M, Chapman S et al. Homeostatic repopulation by CD28-CD8+ T cells in alemtuzumab-depleted kidney transplant recipients treated with reduced immunosuppression. Am J Transplant 2008 8 : 338 347.
30. Merkenschlager M, Terry L, Edwards R, Beverley PC. Limiting dilution analysis of proliferative responses in human lymphocyte populations defined by the monoclonal antibody UCHL1: Implications for differential CD45 expression in T cell memory formation. Eur J Immunol 1988 18 : 1653 1661.
31. Lombardi G, Sidhu S, Daly M, Batchelor JR, Makgoba W, Lechler RI. Are primary alloresponses truly primary? Int Immunol 1990 2 : 9 13.
32. Wu Z, Bensinger SJ, Zhang J et al. Homeostatic proliferation is a barrier to transplantation tolerance. Nat Med 2004 10 : 87 92.